Ovarian Cancer | Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Ovarian Cancer
Featuring perspectives from Drs Mansoor Raza Mirza, Amit M Oza and Richard T Penson, moderated by Dr Joyce F Liu, including the following topics: • Optimal Genomic Evaluation of and Targeted Therapies for Newly Diagnosed Advanced Ovarian Cancer — Dr Mirza o Introduction (0:00) o Case: A morbidly obese woman in her mid 40s who is a Jehovah’s Witness with ovarian cancer and a germline BRCA2 mutation — Lyndsay J Willmott, MD (1:10) o Case: A woman in her early 50s with BRCA wild-type, homologous recombination repair deficiency (HRD)-negative Stage IV ovarian cancer, a large pleural effusion and ascites — Kellie E Schneider, MD (7:16) o Faculty presentation: Dr Mirza (13:51) • PARP Inhibitors for Relapsed/Refractory Ovarian Cancer — Dr Oza o Case: A woman in her mid 60s with recurrent BRCA wild-type ovarian cancer in ongoing and durable remission with paclitaxel/carboplatin followed by maintenance niraparib — John K Chan, MD (26:13) o Case: A woman in her early 50s with a germline BRCA2 mutation and recurrent platinum-sensitive ovarian cancer who received paclitaxel/carboplatin/bevacizumab and maintenance olaparib/bevacizumab — Thomas P Morrissey, MD (32:09) o Faculty presentation: Dr Oza (36:55) • Rationale for and Available Data with PARP Inhibitors in Combination with Other Anticancer Therapies for Advanced Ovarian Cancer — Dr Liu o Case: A woman in her early 20s with newly diagnosed Stage IV, low-grade serous carcinoma of the ovary with pleural effusions — Dana M Chase, MD (48:55) o Case: A woman in her late 40s with high-grade serous ovarian cancer who received neoadjuvant chemotherapy on the Phase III FIRST trial and undergoes R0 debulking surgery — Dr Schneider (52:51) o Faculty presentation: Dr Liu (57:39) • Novel Agents for the Treatment of Ovarian Cancer — Dr Penson o Case: A woman in her mid 60s with multiregimen-refractory metastatic ovarian cancer who receives paclitaxel/tumor treating fields on the INNOVATE-3 trial and develops dermatologic toxicity — Dr Chan (1:07:19) o Cases: A woman in her early 70s with multiple comorbidities and extensively treated recurrent, platinum-resistant BRCA wild-type, HRD-negative, PD-L1-positive, FR-alpha-mutant ovarian cancer and a woman in her mid 40s with a germline BRCA1 mutation and multiregimen-recurrent FR-alpha-mutant carcinomatosis — Dr Chase and Dr Willmott (1:11:00) o Faculty presentation: Dr Penson (1:18:20) CME information and select publications